These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 31889231)

  • 21. A review and recommendations for oral chaperone therapy in adult patients with Fabry disease.
    Nowicki M; Bazan-Socha S; Błażejewska-Hyżorek B; Kłopotowski MM; Komar M; Kusztal MA; Liberek T; Małyszko J; Mizia-Stec K; Oko-Sarnowska Z; Pawlaczyk K; Podolec P; Sławek J;
    Orphanet J Rare Dis; 2024 Jan; 19(1):16. PubMed ID: 38238782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inter-assay variability influences migalastat amenability assessments among Fabry disease variants.
    Oommen S; Zhou Y; Meiyappan M; Gurevich A; Qiu Y
    Mol Genet Metab; 2019 May; 127(1):74-85. PubMed ID: 31036492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
    Welford RWD; Mühlemann A; Garzotti M; Rickert V; Groenen PMA; Morand O; Üçeyler N; Probst MR
    Hum Mol Genet; 2018 Oct; 27(19):3392-3403. PubMed ID: 29982630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fabry Disease: Switch from Enzyme Replacement Therapy to Oral Chaperone Migalastat: What Do We Know Today?
    Perretta F; Jaurretche S
    Healthcare (Basel); 2023 Feb; 11(4):. PubMed ID: 36832983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up of renal function in patients treated with migalastat for Fabry disease.
    Bichet DG; Torra R; Wallace E; Hughes D; Giugliani R; Skuban N; Krusinska E; Feldt-Rasmussen U; Schiffmann R; Nicholls K
    Mol Genet Metab Rep; 2021 Sep; 28():100786. PubMed ID: 34401344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy.
    Lenders M; Stappers F; Niemietz C; Schmitz B; Boutin M; Ballmaier PJ; Zibert A; Schmidt H; Brand SM; Auray-Blais C; Brand E
    J Med Genet; 2019 Aug; 56(8):548-556. PubMed ID: 31010832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fabry Disease: The Current Treatment Landscape.
    Lenders M; Brand E
    Drugs; 2021 Apr; 81(6):635-645. PubMed ID: 33721270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chaperone molecules: The example of Fabry disease].
    Barbey F; Monney P; Dormond O
    Nephrol Ther; 2021 Apr; 17S():S11-S22. PubMed ID: 33910691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutation spectrum of α-Galactosidase gene in Japanese patients with Fabry disease.
    Kobayashi M; Ohashi T; Kaneshiro E; Higuchi T; Ida H
    J Hum Genet; 2019 Jul; 64(7):695-699. PubMed ID: 30988410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fabry disease Enzyme Enhancement on migalastat Study: FEES.
    Kugan M; D'Amore S; Mitra-Royhurst U; Patel S; Burke D; Heales S; Ramaswami U
    Clin Chim Acta; 2024 Jul; 561():119843. PubMed ID: 38964569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes.
    Hughes DA; Bichet DG; Giugliani R; Hopkin RJ; Krusinska E; Nicholls K; Olivotto I; Feldt-Rasmussen U; Sakai N; Skuban N; Sunder-Plassmann G; Torra R; Wilcox WR
    J Med Genet; 2023 Jul; 60(7):722-731. PubMed ID: 36543533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.
    Schiffmann R; Pastores GM; Lien YH; Castaneda V; Chang P; Martin R; Wijatyk A
    Orphanet J Rare Dis; 2014 Nov; 9():169. PubMed ID: 25425121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Agalsidase-β should be proposed as first line therapy in classic male Fabry patients with undetectable α-galactosidase A activity.
    Nowak A; Dormond O; Monzambani V; Huynh-Do U; Barbey F
    Mol Genet Metab; 2022; 137(1-2):173-178. PubMed ID: 36087505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Precision medicine in Fabry disease.
    Lenders M; Brand E
    Nephrol Dial Transplant; 2021 Jun; 36(Suppl 2):14-23. PubMed ID: 34153986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models.
    Besada P; Gallardo-Gómez M; Pérez-Márquez T; Patiño-Álvarez L; Pantano S; Silva-López C; Terán C; Arévalo-Gómez A; Ruz-Zafra A; Fernández-Martín J; Ortolano S
    Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenges in Fabry disease: the combination of two individually amenable
    Fernandes RM; Bento D; Marques N; Azevedo O; Mota T; Costa H; Santo ME; Silva DC; Jesus I
    Future Cardiol; 2023 Jan; 19(1):39-43. PubMed ID: 36695159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study.
    Hughes DA; Nicholls K; Sunder-Plassmann G; Jovanovic A; Feldt-Rasmussen U; Schiffmann R; Giugliani R; Jain V; Viereck C; Castelli JP; Skuban N; Barth JA; Bichet DG
    Am J Med Genet A; 2019 Jun; 179(6):1069-1073. PubMed ID: 30920142
    [No Abstract]   [Full Text] [Related]  

  • 38. An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy.
    Goker-Alpan O; Longo N; McDonald M; Shankar SP; Schiffmann R; Chang P; Shen Y; Pano A
    Drug Des Devel Ther; 2016; 10():1771-81. PubMed ID: 27307708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.
    Lin HY; Huang YH; Liao HC; Liu HC; Hsu TR; Shen CI; Li ST; Li CF; Lee LH; Lee PC; Huang CK; Chiang CC; Lin SP; Niu DM
    J Chin Med Assoc; 2014 Apr; 77(4):190-7. PubMed ID: 24388678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Baseline Characteristics of Fabry Disease "Amenable" Migalastat Patients in Argentinian Cohort.
    Jaurretche S; Alonso S; Calvo M; Fernandez S; Figueredo H; Galli B; Marin I; Martinez A; Mattausch S; Perretta F; Politei J; Rolon JI; Calabrese E
    Glob Health Epidemiol Genom; 2024; 2024():9293896. PubMed ID: 38410281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.